Objective To explore the clinical efficacy,safety,and impact on surgery of camrelizumab combined with docetaxel+nedaplatin for neoadjuvant therapy in patients with stage T3～4a esophageal cancer.Methods The clinical data of 56 patients with locally advanced esophageal cancer who received neoadjuvant therapy in conjunction with radical esophageal cancer surgery admitted to our hospital from Janu-ary 2019 to June 2022 were retrospectively analyzed.The patients were divided into two groups according to different treatments for different years of hospitalization:the combination group(n=26)applied pre-operative chemotherapy with camrelizumab combined with docetaxel+nedaplatin,and the chemotherapy group(n=30)applied pre-operative chemotherapy with docetaxel+nedaplatin.Adverse reactions during neo-adjuvant therapy,impacts on surgery,perioperative indicators,imaging changes and pathologic outcomes were compared between the two groups.Results The pathological complete remission rate of patients in the com-bined group was 23.08％,while that of the control group was 3.33％,the difference was statistically signifi-cant(P＜0.05).The complete remission rate,objective remission rate,and disease control rate of patients in the combined group were higher than those in the chemotherapy group(P＜0.05).There was no statistically significant difference in the incidence of adverse re-actions between the two groups of patients during neoadjuvant therapy(P＞0.05).There was no statis-tically significant difference in perioperative indicators and postoperative complications between the two groups of patients(P＞0.05).There was no statis-tically significant difference in the short-term progression free survival rate and overall survival rate between the two groups of patients(P＞O.05).Conclusion Conclusion Neoadjuvant camrelizumab combined with docetaxel+nedaplatin chemotherapy for T3～T4a stage esophageal cancer is safe and feasible,without increasing the incidence of treatment-related adverse reactions,and shows a good pathological remission rate compared with chemotherapy alone.
国家科技期刊平台
NSTL
万方数据
